1-3 of 3
Filip Razga
Close
Sort by
Journal Articles

ASP210 - a Potent Oligonucleotide-Based Inhibitor for Combating Both BCR-ABL1 Dependent and Independent TKI-Resistant CML Cells

Veronika Nemethova, Petra Mazancova, Boglarka Nemethova, Lucia Uhelska, Andrea Babelova, Michal Selc, Kristina Jakic, Ondrej Mitrovsky, Denisa Myslivcova, Marketa Zackova, Alexandra Poturnayova, Angelika Batorova, Antonia Hatalova, Katarina Slezakova, Lubos Drgona, Iveta Oravcova, Eva Mikuskova, Ludmila Demitrovicova, Andrej Vranovsky, Filip Razga
Journal: Blood
Blood (2022) 140 (Supplement 1): 12995–12996.
https://doi.org/10.1182/blood-2022-166148
Published: 2022
Journal Articles

The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy

Katerina Machova Polakova, Jitka Koblihova, Zuzana Ondrackova, Filip Razga, Vaclava Polivkova, Hana Klamova, Daniela Zackova, Petr Cetkovsky, Marek Trneny, Jiri Mayer, Zdenek Racil
Journal: Blood
Blood (2011) 118 (21): 2495.
https://doi.org/10.1182/blood.V118.21.2495.2495
Published: 2011
Journal Articles

Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy,

Jelena D. Milosevic, Filip Razga, Dana Dvorakova, Tomas Jurcek, Tiina Berg, Ana Puda, Thorsten Klampfl, Ashot Harutyunyan, Bettina Gisslinger, Heinz Gisslinger, MD, Ester Orlandi, Paolo Bernasconi, Karel Indrak, Martina Divoka, Edgar Faber, Jiri Mayer, MD, Zdenek Racil, Robert Kralovics, PhD
Journal: Blood
Blood (2011) 118 (21): 3755.
https://doi.org/10.1182/blood.V118.21.3755.3755
Published: 2011